Event exploring the increasing risk of emerging infectious diseases Update on Appili transaction and recent operational highlights, including $117M submitted in federal funding applications Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics Inc. ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, will be joining at the upcoming Aditxt Weekly Update. The event, scheduled on April 4 at 11:30 am ET, will highlight the urgent need for infectious disease treatm

The event will begin today at 11:30 a.m. ET Event to feature Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt; Chris Mitton, President of Pearsanta; and Dr. Roger Giese, Co-Inventor of the CaSe Platform and Professor Emeritus at Northeastern University Aditxt, Inc. (NASDAQ:ADTX), ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that today's Aditxt Weekly Update will focus on the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. ("Pearsanta"). The proprietary technology is based on adductomics and is designed to assess early DNA changes that may lead to mutations associated with cancer and othe

-- Evofem's Cost to Manufacture PHEXXI will Decrease by 55% - 60% -- SAN DIEGO, March 26, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply Agreement (L&S Agreement) with Windtree Therapeutics, Inc. (NasdaqCM: WINT), under which Windtree will be Evofem's sourcing partner for PHEXXI® (lactic acid, citric acid and potassium bitartrate). This FDA-approved hormone-free contraceptive vaginal gel is applied 0 to 60 minutes before each act of intercourse. It prevents pregnancy by maintaining the normal vaginal biome which has a slightly acidic pH that is inhospitable to sperm.

-- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E

Acquisition is key to Pearsanta's mission of addressing cancer through early detection and prevention Pearsanta plans further validation and regulatory submissions to support commercialization within its Richmond, Virginia CLIA/CAP-certified monitoring center and laboratories Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has acquired key patents related to adductomics-based DNA damage detection, which it believes will further strengthen its position in the cancer prevention-focused diagnostic industry. Pearsanta acquired the patents in exch

WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, is pleased to announce that it has entered into a License and Supply Agreement to become the sourcing partner for Evofem Biosciences, Inc. (OTCQB:EVFM) for one of Evofem's FDA-approved products -- PHEXXI® (lactic acid, citric acid and potassium bitartrate). The product is a first-in-class hormone-free, on-demand prescription contraceptive vaginal gel that women control. PHEXXI annual revenues have gr

Evofem CEO Saundra Pelletier will join Aditxt Co-founder and CEO Amro Albanna to discuss status and future plans Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today provided a corporate update outlining recent achievements and strategic milestones across its subsidiaries and strategic acquisition initiatives. In addition, the Company will be launching Aditxt Weekly Updates, starting Friday March 21, 2025, and continuing throughout the second quarter of 2025. Advancing Toward Key Commercial Milestones As Aditxt continues executing its strategic roadmap, the Company remains fo

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, announced today that it will effect a 1-for-250 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 17, 2025, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the special meeting held on February 28, 2025, with the final ratio determined by the Company's board of directors. As a result of the reverse stock split, the CUSIP number for the Company's common stock will

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update on its subsidiary, Adimune, Inc., ("Adimune") and its progress in advancing ADI-100, an investigational product candidate to be studied in patients with Psoriasis, Type I Diabetes (T1D) and Stiff Person Syndrome. Adimune's mission is to address the root causes of autoimmune diseases. By harnessing the body's natural ability to restore and maintain immune tolerance, Adimune strives to deliver innovative solutions that improve lives without the risks of immunosuppression. As a subsidiary of Aditxt, Adimune continues to advance

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has engaged Dominari Securities LLC as lead underwriter for Pearsanta's planned initial public offering (IPO). The proposed IPO, advised by Dominari Securities, is intended to support Pearsanta's U.S. and international commercial launch efforts and further advance its Mitomic® Technology platform for early cancer detection and diagnosis. Pearsanta is developing a non-invasive blood-based test designed to detect cancer at earlier stages when treatment outcomes are more favorable. The C

4 - Evofem Biosciences, Inc. (0001618835) (Issuer)

4 - Evofem Biosciences, Inc. (0001618835) (Issuer)

5 - Evofem Biosciences, Inc. (0001618835) (Issuer)

4 - Evofem Biosciences, Inc. (0001618835) (Issuer)

3 - Evofem Biosciences, Inc. (0001618835) (Issuer)

3 - Evofem Biosciences, Inc. (0001618835) (Issuer)

3 - Evofem Biosciences, Inc. (0001618835) (Issuer)

4 - Evofem Biosciences, Inc. (0001618835) (Issuer)

4 - Evofem Biosciences, Inc. (0001618835) (Issuer)

4 - Evofem Biosciences, Inc. (0001618835) (Issuer)

10-K/A - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

10-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

10-Q - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders. Throughout her career, Ms. Hermina has advised NYSE and NASDAQ listed companies on governance best practices and developed communication strategies tailored to retail and institutional investors. As Senior Vice

Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), appointed Christoper Mitton as President. Christopher Mitton brings over 20 years of leadership experience in the medical diagnostics industry, with a strong focus on personalized healthcare and molecular oncology diagnostics. He has a proven track record in building and leading successful commercial operations, underpinned by his deep expertise in product commercialization, business development, and strategic sales and marketing. Mr. Mitton continues to serve as

SAN DIEGO, April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB:EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and Secretary, effective April 13, 2023. Reporting to Chief Executive Officer Saundra Pelletier, Ms. Zhang will lead Evofem's finance organization and financial activities including financial planning and analysis, accounting, external audit, tax, controllership, and treasury functions. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Bioscien

SAN DIEGO, March 9, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) is pleased to announce the appointment of Albert Altro as Interim Chief Financial Officer of the Company. He replaces Jay File, who is leaving the Company to explore other opportunities. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Mr. Altro brings over 25 years of financial and operational experience including corporate restructuring, public accounting and executive management, and consulting, primarily in a leadership rol

SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) today announced the appointment of Jenny Yip, a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors. The appointment of Ms. Yip as a director expands the Board from five to six independent directors. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "Now more than ever, this is the time to align and support organizations like Evofem with a sustainable future, which are dedicated to impr

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Dr. Brandi Howard as Chief Clinical Officer and member of the company's Executive Committee, effective May 9, 2022. Dr. Howard, who brings to ObsEva more than 20 years of women's health expertise, will be responsible for the Company's clinical development and medical affairs strategy. She succeeds Dr. Elizabeth Garner, who will be departing the Company on May 6, 2022 to pursue a new opportunity. To help ensure a smooth tra

Fedasz will Focus on Opening New Markets for Evofem's First - and Only – in-Class Contraceptive, Phexxi® (lactic acid, citric acid, and potassium bitartrate)SAN DIEGO, April 11, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Karina Fedasz as its Head of Business Development. At Evofem, Karina will oversee the company's business development, product and pipeline portfolios, new business ventures, and the advancement of access partnerships around the world. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

Morgan Stanley reiterated coverage of Evofem Biosciences with a rating of Underweight and set a new price target of $0.53 from $0.50 previously

HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $2.00 from $2.50 previously

HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $2.50 from $4.00 previously

Morgan Stanley downgraded Evofem Biosciences from Equal-Weight to Underweight and set a new price target of $0.80

Morgan Stanley reiterated coverage of Evofem Biosciences with a rating of Equal-Weight and set a new price target of $1.00 from $3.00 previously

HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $4.00 from $7.00 previously

HC Wainwright reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $7.00 from $8.00 previously

HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $7.00 from $8.00 previously

-- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E

— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,

— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. commercial agreement for Phexxi in Middle East — SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

Evofem Acquires SOLOSEC, an FDA-Approved Single-Dose Treatment for Bacterial Vaginosis and Trichomoniasis Aditxt, Inc. ("Aditxt") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12th, Aditxt, its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc.'s ("Evofem") (OTCQB:EVFM) amended and restated their Merger Agreement. This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem's future success, including interim financing needs. The other revisions to the Merger Agreement, alongside additional interim financing for Evofem, include substit

SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Received $1 million from Aditxt, Inc. (NASDAQ:ADTX) in May 2024 in consideration for reinstating and amending

-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the most favorable ratio since the Phexxi launch -- SAN DIEGO, March 27, 2024 /PRNewswire/ -- The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofe

— On track to achieve third consecutive year of revenue growth – — Third consecutive quarter of favorable sales and marketing expense as a percentage of net sales — — Reduced loss from operations by 81% vs. Q3 2022 — SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> $5.1 million in net product sales of Phexxi® (la

— On track to achieve third consecutive year of revenue growth – — Second consecutive quarter of favorable net product sales to sales and marketing expense ratio — — Reduced total operating expenses 68% — — Decreased loss from operations by 70% — SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2023. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "This marks the second consecutive quarter in which our

-- Increased net product revenue 37% in the first quarter of 2023 vs. prior year quarter -- -- Reduced operating expenses 72% -- -- Decreased loss from operations by 88% -- -- Reaffirms path to positive EBITDA -- SAN DIEGO, June 16, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFMD) today announced financial results for the first quarter of 2023, including growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate). EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

-- Net product sales more than doubled in 2022 vs. prior year -- -- Reduced total operating expenses by $74.1 million in 2022 vs. 2021, exceeding stated goal -- -- Evofem targeting EBITDA break-even by year-end 2023 -- SAN DIEGO, April 28, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), has reported financial results for the year ended December 31, 2022. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Highlights include